FDA Selects Patient-Led Nonprofit to Develop Pancreatitis Flare Endpoint for Clinical Trials

Mission: Cure joins FDA's Rare Disease Endpoint Advancement Pilot Program as the agency calls for putting the patient's voice at the center of rare disease drug development NEW YORK, Oct. 27, 2026 /PRNewswire/ -- Mission: Cure (https://mission-cure.org), a patient-led nonprofit working to...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.